Business Description
AstraZeneca PLC
ISIN : GB0009895292
Compare
Compare
Traded in other countries / regions
AZN.UKAZN.USAAZN.SwedenZEG.GermanyA1ZN34.BrazilAZN.ArgentinaAZNN.MexicoZEG.BulgariaAZNA.Austria IPO Date
2022-11-14Description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.85 | |||||
| Debt-to-EBITDA | 2.36 | |||||
| Interest Coverage | 5.92 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.78 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 14 | |||||
| 3-Year EPS without NRI Growth Rate | 37.2 | |||||
| 3-Year FCF Growth Rate | 38.8 | |||||
| 3-Year Book Growth Rate | 31.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 33.24 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.55 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.89 | |||||
| Quick Ratio | 0.69 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 221.96 | |||||
| Days Sales Outstanding | 78.67 | |||||
| Days Payable | 694.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 2.9 | |||||
| 3-Year Average Share Buyback Ratio | -5.7 | |||||
| Shareholder Yield % | 2.13 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.08 | |||||
| Operating Margin % | 19.96 | |||||
| Net Margin % | 13.1 | |||||
| FCF Margin % | 14.18 | |||||
| ROE % | 16.87 | |||||
| ROA % | 6.43 | |||||
| ROIC % | 9.53 | |||||
| 3-Year ROIIC % | 11.23 | |||||
| ROC (Joel Greenblatt) % | 91.61 | |||||
| ROCE % | 13.14 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.69 | |||||
| Forward PE Ratio | 8.33 | |||||
| PE Ratio without NRI | 30.88 | |||||
| Shiller PE Ratio | 57.02 | |||||
| Price-to-Owner-Earnings | 23.44 | |||||
| PEG Ratio | 4.83 | |||||
| PS Ratio | 4.43 | |||||
| PB Ratio | 5.51 | |||||
| Price-to-Free-Cash-Flow | 31.17 | |||||
| Price-to-Operating-Cash-Flow | 19.65 | |||||
| EV-to-EBIT | 25.74 | |||||
| EV-to-Forward-EBIT | 16.56 | |||||
| EV-to-EBITDA | 17.17 | |||||
| EV-to-Forward-EBITDA | 13.56 | |||||
| EV-to-Revenue | 4.92 | |||||
| EV-to-Forward-Revenue | 4.83 | |||||
| EV-to-FCF | 34.64 | |||||
| Price-to-Projected-FCF | 2.64 | |||||
| Price-to-DCF (Earnings Based) | 0.51 | |||||
| Price-to-DCF (FCF Based) | 1.19 | |||||
| Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.33 | |||||
| Earnings Yield (Greenblatt) % | 3.89 | |||||
| FCF Yield % | 3.23 | |||||
| Forward Rate of Return (Yacktman) % | 11.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AstraZeneca PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil лв) | 88,314.357 | ||
| EPS (TTM) (лв) | 7.441 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (лв) | 0.000931 | ||
| 20-Day SMA (лв) | 142.2 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (лв) | 142.2 - 143.05 | ||
| Shares Outstanding (Mil) | 1,550.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AstraZeneca PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AstraZeneca PLC Stock Events
| Event | Date | Price(лв) | ||
|---|---|---|---|---|
| No Event Data | ||||
AstraZeneca PLC Frequently Asked Questions
What is AstraZeneca PLC(XBUL:ZEG)'s stock price today?
The current price of XBUL:ZEG is лв142.20. The 52 week high of XBUL:ZEG is лв143.05 and 52 week low is лв142.20.
When is next earnings date of AstraZeneca PLC(XBUL:ZEG)?
The next earnings date of AstraZeneca PLC(XBUL:ZEG) is 2024-11-12.
Does AstraZeneca PLC(XBUL:ZEG) pay dividends? If so, how much?
AstraZeneca PLC(XBUL:ZEG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers